Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical & Experimental Metastasis
Erschienen in: Clinical & Experimental Metastasis 4/2018

08.06.2018 | Research Paper

The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Epithelial mesenchymal transition (EMT) describes the shift of cells from an epithelial form to a contact independent, migratory, mesenchymal form. In cancer the change is linked to invasion and metastasis. Tumour conditions, including hypoxia, acidosis and a range of treatments can trigger EMT, which is implicated in the subsequent development of resistance to those same treatments. Consequently, the degree to which EMT occurs may underpin the entire course of tumour progression and treatment response in a patient. In this review we look past the protective effect of EMT against the initial treatment, to the role of the mesenchymal state, once triggered, in promoting disease growth, spread and future treatment insensitivity. In patients a correlation was found between the propensity of a treatment to induce EMT and failure of that treatment to provide a survival benefit, implicating EMT induction in accelerated tumour progression after treatment cessation. Looking to the mechanisms driving this detrimental effect; increased proliferation, suppressed apoptosis, stem cell induction, augmented angiogenesis, enhanced metastatic dissemination, and immune tolerance, can all result from treatment-induced EMT and could worsen outcome. Evidence also suggests EMT induction with earlier therapies attenuates benefits of later treatments. Looking beyond epithelial tumours, de-differentiation also has therapy-attenuating effects and reversal thereof may yield similar rewards. A range of potential therapies are in development that may address the diverse mechanisms and molecular control systems involved in EMT-induced accelerated progression. Considering the broad reaching effects of mesenchymal shift identified, successful deployment of such treatments could substantially improve patient outcomes.
Literatur
1.
Halbleib J, Nelson WJ (2006) Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 20(23):3199–3214PubMedCrossRef
2.
Kawano S, Asano M, Adachi Y, Matsui J (2016) Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res 36(4):1553–1561PubMed
3.
Ekblom P (1989) Developmentally regulated conversion of mesenchyme to epithelium. FASEB J 3(10):2141–2150PubMedCrossRef
4.
5.
6.
7.
Tan T, Miow Q, Miki Y, Noda T, Mori S, Huang R, Thiery J (2014) Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 6(10):1279–1293PubMedPubMedCentralCrossRef
8.
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68(4):989–997PubMedCrossRef
9.
10.
11.
Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130(2):449–455. https://​doi.​org/​10.​1007/​s10549-011-1373-x PubMedCrossRef
12.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584. https://​doi.​org/​10.​1126/​science.​1228522 PubMedPubMedCentralCrossRef
13.
Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW (2010) Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15(2):235–252. https://​doi.​org/​10.​1007/​s10911-010-9175-z PubMedCrossRef
14.
15.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715PubMedPubMedCentralCrossRef
16.
Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3(8):e2888PubMedPubMedCentralCrossRef
17.
18.
Cao Z, Livas T, Kyprianou N (2016) Anoikis and EMT: lethal “liaisons” during cancer progression. Critical reviews in oncogenesis 21(3–4):155–168PubMedPubMedCentralCrossRef
19.
Chao YL, Shepard CR, Wells A (2010) Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9:179PubMedPubMedCentralCrossRef
20.
21.
Gunasinghe NPAD., Wells A, Thompson E, Hugo H (2012) Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 31(3–4):469–478PubMedCrossRef
22.
23.
24.
Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y (2011) Direct targeting of Sec23a by miR-200 s influences cancer cell secretome and promotes metastatic colonization. Nature Med 17(9):1101–1108. https://​doi.​org/​10.​1038/​nm.​2401 PubMedCrossRef
25.
26.
Krebs A, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton V, Pilarsky C, Winkler T, Brabletz S, Stemmler M, Brabletz T (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19(5):518–529PubMedCrossRef
27.
28.
29.
30.
31.
32.
Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, De Clercq S, Minguijón E, Balsat C, Sokolow Y, Dubois C, De Cock F, Scozzaro S, Sopena F, Lanas A, D’Haene N, Salmon I, Marine J-C, Voet T, Sotiropoulou P, Blanpain C (2018) Identification of the tumour transition states occurring during EMT. Nature 556(7702):463–468PubMedCrossRef
33.
34.
Celià-Terrassa T, Meca-Cortés Ó, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, ρlvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, García de Herreros A, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM (2012) Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Investig 122(5):1849–1868. https://​doi.​org/​10.​1172/​JCI59218 PubMedCrossRef
35.
36.
Fidler IJ (1973) The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 9(3):223–227PubMedCrossRef
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
Nagathihalli N, Massion P, Gonzalez A, Lu P, Datta P (2012) Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther 11(11):2362–2372PubMedPubMedCentralCrossRef
47.
48.
Yang M-H, Hsu D, Wang H-J, Lan H-Y, Yang W-H, Huang C-H, Kao S-Y, Tzeng C-H, Tai S-K, Chang S-Y, Lee O, Wu K-J (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12(10):982–992PubMedCrossRef
49.
Sánchez Tilló E, Lázaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A (2010) ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29(24):3490–3500PubMedCrossRef
50.
Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn C-O, Heidecke C-D, Friess H, Büchler M, Evert M, Lerch M, Weiss F (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61(3):439–448PubMedCrossRef
51.
Liao W, Jordaan G, Srivastava MK, Dubinett S, Sharma S, Sharma S (2013) Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer. Am J Cancer Res 3(4):374–389PubMedPubMedCentral
52.
Sharma S, Lichtenstein A (2009) Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood 114(19):4179–4185PubMedPubMedCentralCrossRef
53.
54.
55.
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM (2014) Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 145(3):593–604. https://​doi.​org/​10.​1007/​s10549-014-2979-6 PubMedPubMedCentralCrossRef
56.
Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H (2016) HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 35(29):3781–3795. https://​doi.​org/​10.​1038/​onc.​2015.​444 PubMedCrossRef
57.
58.
59.
60.
Zhu Q-C, Gao R-Y, Wu W, Qin H-L (2013) Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev 14(5):2689–2698PubMedCrossRef
61.
Xu S, Chheda C, Ouhaddi Y, Benhaddou H, Bourhim M, Grippo P, Principe D, Mascariñas E, DeCant B, Tsukamoto H, Pandol S, Edderkaoui M (2015) Characterization of mouse models of early pancreatic lesions induced by alcohol and chronic pancreatitis. Pancreas 44(6):882–887PubMedPubMedCentralCrossRef
62.
63.
Yang S, Da Zhang L, Xiong Y, Zhang Y, Li H, Li X, Dong J (2009) HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun 382(3):555–560PubMedCrossRef
64.
Shen H-J, Sun Y-H, Zhang S-J, Jiang J-X, Dong X-W, Jia Y-L, Shen J, Guan Y, Zhang L-H, Li F-F, Lin X-X, Wu X-M, Xie Q-M, Yan X-F (2014) Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation. Biochim Biophys Acta 1840 (6):1838–1849PubMedCrossRef
65.
66.
Liu Z, Tu K, Wang Y, Yao B, Li Q, Wang L, Dou C, Liu Q, Zheng X (2017) Hypoxia accelerates aggressiveness of hepatocellular carcinoma cells involving oxidative stress, epithelial-mesenchymal transition and non-canonical hedgehog signaling. Cell Physiol Biochem 44(5):1856–1868PubMedCrossRef
67.
68.
69.
Peppicelli S, Bianchini F, Torre E, Calorini L (2014) Contribution of acidic melanoma cells undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic melanoma cells. Clin Exp Metastasis 31(4):423–433PubMedCrossRef
70.
Deng S, Li X, Niu Y, Zhu S, Jin Y, Chen J, Liu Y, He C, Yin T, Yang Z, Tao J, Xiong J, Wu H, Wang C, Zhao G (2015) MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget 6(37):39661–39675PubMedPubMedCentralCrossRef
71.
Suzuki A, Maeda T, Baba Y, Shimamura K, Kato Y (2014) Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model. Cancer Cell Int 14(1):129–129PubMedPubMedCentralCrossRef
72.
Marín-Hernández Á, Gallardo-Pérez JC, Hernández Reséndiz I, Del Mazo-Monsalvo I, Robledo-Cadena DX, Moreno Sánchez R, Rodríguez Enríquez S (2017) Hypoglycemia enhances epithelial-mesenchymal transition and invasiveness, and restrains the warburg phenotype, in hypoxic HeLa cell cultures and microspheroids. J Cell Physiol 232(6):1346–1359PubMedCrossRef
73.
74.
75.
76.
77.
Yan Y-R, Xie Q, Li F, Zhang Y, Ma J-W, Xie S-M, Li H-Y, Zhong X-Y (2014) Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells. Neuropathology 34(2):128–134PubMedCrossRef
78.
Xiong H, Hong J, Du W, Lin Y-W, Ren L-L, Wang Y-C, Su W-Y, Wang J-L, Cui Y, Wang Z-H, Fang J-Y (2012) Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 287(8):5819–5832PubMedCrossRef
79.
80.
81.
82.
83.
84.
Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, Liu Y, Yu M, Ma Y, Guo N, Shi M (2015) Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6(7):5072–5087PubMedCrossRef
85.
86.
87.
Ramsdale R, Jorissen R, Li F, Al Obaidi S, Ward T, Sheppard K, Bukczynska P, Young R, Boyle S, Shackleton M, Bollag G, Long G, Tulchinsky E, Rizos H, Pearson R, McArthur G, Dhillon A, Ferrao P (2015) The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci Signal 8(390):ra82PubMedCrossRef
88.
Miyazaki S, Kikuchi H, Iino I, Uehara T, Setoguchi T, Fujita T, Hiramatsu Y, Ohta M, Kamiya K, Kitagawa K, Kitagawa M, Baba S, Konno H (2014) Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer 135(2):295–307PubMedCrossRef
89.
Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, Matsumoto T, Matsuura N, Ohta M, Okumura M (2011) Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 92(5):1794–1804. (discussion 1804)PubMedCrossRef
90.
Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira MV, Jimenez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascon P, Mellado B (2014) Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther 13(5):1270–1284. https://​doi.​org/​10.​1158/​1535-7163.​MCT-13-0775 PubMedCrossRef
91.
92.
Redfern AD, McLaren SA, Dissanayake V, Chan A, Zeps N, Dobrovic A, Soon L, Thompson EW, Christobel SM (2016) Predictive value of de novo and induced epithelial-mesenchymal transition in locally advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Res 76(4 Suppl):P1-05-03CrossRef
93.
94.
95.
Fifis T, Nguyen L, Malcontenti Wilson C, Chan L, Nunes Costa P, Daruwalla J, Nikfarjam M, Muralidharan V, Waltham M, Thompson E, Christophi C (2013) Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor. Cancer Med 2(5):595–610PubMedPubMedCentral
96.
Nörz D, Grottke A, Bach J, Herzberger C, Hofmann B, Nashan B, Jücker M, Ewald F (2015) Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cell Signal 27(11):2191–2200PubMedCrossRef
97.
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764. https://​doi.​org/​10.​1200/​jco.​1996.​14.​6.​1756 PubMedCrossRef
98.
Li C, Xiang A, Chen X, Yin K, Lu J, Yin W (2017) Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials. OncoTargets Ther 10:3155–3168. https://​doi.​org/​10.​2147/​OTT.​S138600 CrossRef
99.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. https://​doi.​org/​10.​1073/​pnas.​0905718106 PubMedCrossRef
100.
Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz J, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR (2015) Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33(9):1045–1052PubMedCrossRef
101.
Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo P-H, Vella LJ, Goding CR, Cebon J, Behren A (2014) Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget 5(14):5782–5797PubMedPubMedCentralCrossRef
102.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O’Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323–332. https://​doi.​org/​10.​1016/​S1470-2045(14)70012-9 PubMedPubMedCentralCrossRef
103.
de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie M, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154PubMedCrossRef
104.
105.
Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870–884. https://​doi.​org/​10.​1007/​s12325-013-0060-1 PubMedPubMedCentralCrossRef
106.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357–2362PubMedCrossRef
107.
108.
Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman P, Awada A (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148(3):553–561PubMedPubMedCentralCrossRef
109.
Schöffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha S, Blay J-Y, Hohenberger P, D’Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri G, Patel S (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629–1637PubMedCrossRef
110.
Demetri G, Schöffski P, Grignani G, Blay J-Y, Maki R, Van Tine B, Alcindor T, Jones R, D’Adamo D, Guo M, Chawla S (2017) Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 35(30):3433–3439PubMedCrossRef
111.
Shah P, Gau Y, Sabnis G (2014) Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat 143(1):99–111PubMedCrossRef
112.
Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31(17):2128–2135. https://​doi.​org/​10.​1200/​JCO.​2012.​43.​7251 PubMedPubMedCentralCrossRef
113.
Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NPAD., Pinto C, Soo ETL, van Denderen BJW, Hill P, Ramsay RG, Sarcevic B, Newgreen DF, Thompson EW (2013) Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res 15(6):R113-R113. https://​doi.​org/​10.​1186/​bcr3580 CrossRef
114.
115.
Li J, Yang S, Yan W, Yang J, Qin Y-J, Lin X-L, Xie R-Y, Wang S-C, Jin W, Gao F, Shi J-W, Zhao W-T, Jia J-S, Shen H-F, Ke J-R, Liu B, Zhao Y-Q, Huang W-H, Yao K-T, Li D-J, Xiao D (2015) MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest 95(9):1056–1070PubMedCrossRef
116.
117.
Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra M, Lucidi A, Ferrandina G, Natali P, Bagnato A (2011) Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17(8):2350–2360PubMedCrossRef
118.
Sánchez Tilló E, Fanlo L, Siles L, Montes Moreno S, Moros A, Chiva Blanch G, Estruch R, Martinez A, Colomer D, Győrffy B, Roué G, Postigo A (2014) The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ 21(2):247–257PubMedCrossRef
119.
Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J, Xu Y (2016) NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int J Oncol 48(1):225–234PubMedCrossRef
120.
Willipinski Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11(22):8006–8014PubMedCrossRef
121.
Seshadri R, Raymond WA, Leong AS, Horsfall DJ, McCaul K (1996) Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 67(3):353–356PubMedCrossRef
122.
Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutiérrez Avignó F, Peiró G, Barnadas A, Lerma E (2011) Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 42(1):103–110PubMedCrossRef
123.
Withers HR, Taylor JM, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27(2):131–146PubMedCrossRef
124.
125.
Maciejewski B, Majewski S (1991) Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21(3):163–170PubMedCrossRef
126.
Stephens TC, Peacock JH (1977) Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 36(3):313–321PubMedPubMedCentralCrossRef
127.
Wu L, Tannock I (2003) Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 63(9):2134–2138PubMed
128.
Wu C-T, Chen W-C, Liao S-K, Hsu C-L, Lee K-D, Chen M-F (2007) The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 14(3):633–643PubMedCrossRef
129.
Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, Luboinski B, Malaise EP, Eschwege F (1994) Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 104(4):468–472PubMedCrossRef
130.
131.
132.
Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y (2015) Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 136(7):1504–1514PubMedCrossRef
133.
Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC (2014) Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res 16(3):R62-R62. https://​doi.​org/​10.​1186/​bcr3675 CrossRef
134.
135.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2(1):78–91. https://​doi.​org/​10.​1016/​j.​stemcr.​2013.​11.​009 CrossRef
136.
137.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A, Dewhirst M, Bigner D, Rich J (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760PubMedCrossRef
138.
139.
140.
141.
Gu A, Jie Y, Yao Q, Zhang Y, Mingyan E (2017) Slug is associated with tumor metastasis and angiogenesis in ovarian cancer. Reprod Sci 24(2):291–299PubMedCrossRef
142.
143.
Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, Germanwala AV, Elder JB, Ray-Chaudhury A, Yao Y, Gilbert MR, Lonser RR, Heiss JD, Brady RO, Mao Y, Qin J, Zhuang Z (2015) Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Oncotarget 6(14):11882–11893PubMedPubMedCentralCrossRef
144.
Luo J, Lubaroff DM, Hendrix MJ (1999) Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 59(15):3552–3556PubMed
145.
Llorens A, Rodrigo I, López Barcons L, Gonzalez Garrigues M, Lozano E, Vinyals A, Quintanilla M, Cano A, Fabra A (1998) Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Lab Invest 78(9):1131–1142PubMed
146.
147.
Yang W-H, Lan H-Y, Huang C-H, Tai S-K, Tzeng C-H, Kao S-Y, Wu K-J, Hung M-C, Yang M-H (2012) RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol 14(4):366–374PubMedCrossRef
148.
149.
Kudo Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15(3):195–206PubMedCrossRef
150.
Muraoka Cook R, Kurokawa H, Koh Y, Forbes J, Roebuck LR, Barcellos Hoff M, Moody S, Chodosh L, Arteaga C (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64(24):9002–9011PubMedCrossRef
151.
Kakeji Y, Maehara Y, Ikebe M, Teicher BA (1997) Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 37(5):1115–1123PubMedCrossRef
152.
Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA (1994) Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Investig 93(2):892–899PubMedCrossRef
153.
Skowron MA, Niegisch G, Fritz G, Arent T, van Roermund JGH, Romano A, Albers P, Schulz WA, Hoffmann MJ (2015) Phenotype plasticity rather than repopulation from CD90/CK14 + cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. J Exp Clinical Cancer Res 34:144. https://​doi.​org/​10.​1186/​s13046-015-0259-x CrossRef
154.
155.
156.
157.
van Putten LM, Kram LK, van Dierendonck HH, Smink T, Füzy M (1975) Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int J Cancer 15(4):588–595PubMedCrossRef
158.
Vollmer TL, Conley FK (1984) Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells. Cancer Res 44(9):3902–3906PubMed
159.
160.
161.
Chen L, Xiong Y, Li J, Zheng X, Zhou Q, Turner A, Wu C, Lu B, Jiang J (2017) PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem 42(6):2267–2280PubMedCrossRef
162.
Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou Gharios G, Nakamura H, Kawashiri S (2017) Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol 50(1):41–48PubMedCrossRef
163.
164.
165.
McNiel EA, Tsichlis PN (2017) Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduction Targeted Ther 2:16045. https://​doi.​org/​10.​1038/​sigtrans.​2016.​45 CrossRef
166.
Yao J, Caballero O, Huang Y, Lin C, Rimoldi D, Behren A, Cebon J, Hung M-C, Weinstein J, Strausberg R, Zhao Q (2016) Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial-mesenchymal status and tumor-associated immune cytolytic activity. Cancer Immunol Res 4(6):552–561PubMedCrossRef
167.
Lou Y, Diao L, Cuentas ERP, Denning W, Chen L, Fan Y, Byers L, Wang J, Papadimitrakopoulou V, Behrens C, Rodriguez J, Hwu P, Wistuba I, Heymach J, Gibbons D (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 22(14):3630–3642PubMedPubMedCentralCrossRef
168.
Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan Y, Byers LA, Wang J, Papadimitrakopoulou V, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Res 22(14):3630–3642. https://​doi.​org/​10.​1158/​1078-0432.​CCR-15-1434 CrossRef
169.
170.
Qiu X, Hu D, Chen W-Q, Chen R, Qian S, Li C, Li Y, Xiong X, Liu D, Pan F, Yu S, Chen X (2018) PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta 1864(5):1754–1769PubMedCrossRef
171.
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX-F (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241–5241. https://​doi.​org/​10.​1038/​ncomms6241 PubMedPubMedCentralCrossRef
172.
Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin Kuo M-S, Boissier E, Dessoliers M-C, Robin A, Casiraghi O, Even C, Temam S, Olaussen K, Soria J-C, Postel Vinay S (2018) TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open 3(1):e000257PubMedPubMedCentralCrossRef
173.
174.
Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M, Okumura M (2017) Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep 38(4):2277–2284PubMedCrossRef
175.
Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen DJM, Feun LG, Kuo MT, Savaraj N (2017) Relationship of metabolic alterations and PD-L1 expression in cisplatin resistant lung cancer. Cell Dev Biol 6(2):183PubMedPubMedCentral
176.
177.
Eisenhauer EA, Trudeau M (1995) An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A(Suppl 4):S11–S13
178.
179.
Kwok W, Ling M-T, Lee T-W, Lau TCM, Zhou C, Zhang X, Chua C, Chan K, Chan F, Glackin C, Wong Y-C, Wang X (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65(12):5153–5162PubMedCrossRef
180.
Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K (2009) Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 69(7):3148–3156PubMedCrossRef
181.
182.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states. Br J Cancer 110(6):1497–1505. https://​doi.​org/​10.​1038/​bjc.​2014.​80 PubMedPubMedCentralCrossRef
183.
Chiu LY, Hsin IL, Yang TY, Sung WW, Chi JY, Chang JT, Ko JL, Sheu GT (2017) The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. Oncogene 36(2):242–253PubMedCrossRef
184.
185.
186.
Behbahani G, Ghahhari N, Javidi M, Molan A, Feizi N, Babashah S (2017) MicroRNA-mediated post-transcriptional regulation of epithelial to mesenchymal transition in cancer. Pathol Oncol Res 23(1):1–12PubMedCrossRef
187.
188.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker Radtke A, McConkey D, Bar Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060–5072PubMedPubMedCentralCrossRef
189.
Slaby O, Laga R, Sedlacek O (2017) Therapeutic targeting of non-coding RNAs in cancer. Biochem J 474(24):4219–4251PubMedCrossRef
190.
van Zandwijk N, Pavlakis N, Kao S, Linton A, Boyer M, Clarke S, Huynh Y, Chrzanowska A, Fulham M, Bailey D, Cooper W, Kritharides L, Ridley L, Pattison S, MacDiarmid J, Brahmbhatt H, Reid G (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18(10):1386–1396PubMedCrossRef
191.
Zhao J, Dong D, Sun L, Zhang G (2014) Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. Int Braz J Urol 40(2):179–189PubMedCrossRef
192.
193.
Witta S, Gemmill R, Hirsch F, Coldren C, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan D, Sugita M, Chan Z, Baron A, Franklin W, Drabkin H, Girard L, Gazdar A, Minna J, Bunn P (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2):944–950PubMedCrossRef
194.
Ren J, Chen Y, Song H, Chen L, Wang R (2013) Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem 114(6):1395–1403PubMedCrossRef
195.
Garcia Bloj B, Moses C, Sgro A, Plani Lam J, Arooj M, Duffy C, Thiruvengadam S, Sorolla A, Rashwan R, Mancera R, Leisewitz A, Swift Scanlan T, Corvalan A, Blancafort P (2016) Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget 7(37):60535–60554PubMedPubMedCentralCrossRef
196.
197.
Buonato J, Lazzara M (2014) ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res 74(1):309–319PubMedCrossRef
198.
Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R, Lander E (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645–659PubMedPubMedCentralCrossRef
199.
200.
Saini NYX (2017) Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin 2017:1–11
201.
Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch M-E (2017) The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer 9:495–514. https://​doi.​org/​10.​2147/​BCTT.​S139963 PubMedCrossRef
202.
Kast R, Skuli N, Karpel Massler G, Frosina G, Ryken T, Halatsch M-E (2017) Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. Oncotarget 8(37):60727–60749PubMedPubMedCentralCrossRef
203.
el Ghouzzi V, Le Merrer M, Perrin Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato Bellemin AL, Munnich A, Bonaventure J (1997) Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 15(1):42–46PubMedCrossRef
204.
Chen ZF, Behringer RR (1995) twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9(6):686–699PubMedCrossRef
205.
206.
Palumbo ZK, Soare A, Zerr P, Liebl A, Mancuso R, Tomcik M, Sumova B, Dees C, Chen C-W, Wohlfahrt T, Mallano T, Distler A, Ramming A, Gelse K, Mihai C, Distler O, Schett G, Distler JHW (2017) Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. Ann Rheum Dis 76(1):244–251CrossRef
207.
208.
Dong C-Y, Liu X-Y, Wang N, Wang L-N, Yang B-X, Ren Q, Liang H-Y, Ma X-T (2014) Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells 32(12):3173–3182PubMedCrossRef
209.
210.
211.
Šošić D, Richardson J, Yu K, Ornitz D, Olson E (2003) Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112(2):169–180PubMedCrossRef
212.
213.
214.
Simon Tillaux N, Hertig A (2017) Snail and kidney fibrosis. Nephrol Dial Transplant 32(2):224–233PubMed
215.
216.
217.
Takagi T, Moribe H, Kondoh H, Higashi Y (1998) DeltaEF1, a zinc finger and homeodomain transcription factor, is required for skeleton patterning in multiple lineages. Development 125(1):21–31PubMed
218.
Van de Putte T, Maruhashi M, Francis A, Nelles L, Kondoh H, Huylebroeck D, Higashi Y (2003) Mice lacking Zfhx1b, the gene that codes for smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of hirschsprung disease–mental retardation syndrome. Am J Hum Genet 72(2):465–470PubMedPubMedCentralCrossRef
219.
220.
221.
Li J, Riedt T, Goossens S, Carrillo García C, Szczepanski S, Brandes M, Pieters T, Dobrosch L, Gütgemann I, Farla N, Radaelli E, Hulpiau P, Mallela N, Fröhlich H, La Starza R, Matteucci C, Chen T, Brossart P, Mecucci C, Huylebroeck D, Haigh J, Janzen V (2017) The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling. Blood 129(4):460–472PubMedCrossRef
222.
223.
Denecker G, Vandamme N, Akay Ö, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G (2014) Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 21(8):1250–1261. https://​doi.​org/​10.​1038/​cdd.​2014.​44 PubMedPubMedCentralCrossRef
224.
225.
Ishikawa T, Shimizu T, Ueki A, Yamaguchi S, Onishi N, Sugihara E, Kuninaka S, Miyamoto T, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Mabuchi Y, Matsuzaki Y, Yamaguchi R, Miyano S, Saya H (2013) Twist2 functions as a tumor suppressor in murine osteosarcoma cells. Cancer Sci 104(7):880–888PubMedCrossRef
226.
227.
228.
229.
230.
231.
232.
Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91. Group. Blood 82(11):3241–3249PubMed
233.
Dutcher J, Lee S, Gallagher R, Makary A, Hines J, Londer H, Farnen J, Bennett J, Paietta E, Rowe J, Goloubeva O, Wiernik P (2005) Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993). Leuk Lymphoma 46(3):377–385PubMedCrossRef
234.
Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S (1995) All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 19(3–4):277–280PubMedCrossRef
235.
Yang J-Z, Lian W-G, Sun L-X, Qi D-W, Ding Y, Zhang X-H (2016) High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. Pathol Res Pract 212(3):210–216PubMedCrossRef
236.
Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon F-X, Dumontet C, Puisieux A, Nicolini F, Maguer Satta V (2011) Deregulation of TWIST-1 in the CD34 + compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 117(5):1673–1676PubMedCrossRef
237.
Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao Z-H, Zhu Y, Tan W (2013) Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. J Pharmacol Sci 122(4):299–304PubMedCrossRef
238.
Mancini M, Petta S, Iacobucci I, Salvestrini V, Barbieri E, Santucci M (2010) Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell Signal 22(8):1247–1253PubMedCrossRef
239.
Sun Y, Pan J, Mao S, Jin J (2014) IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression. PLoS ONE 9(12):e114647PubMedPubMedCentralCrossRef
240.
Lemma S, Karihtala P, Haapasaari K-M, Jantunen E, Soini Y, Bloigu R, Pasanen A-K, Turpeenniemi Hujanen T, Kuittinen O (2013) Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology 62(2):326–333PubMedCrossRef
241.
Stavropoulou V, Kaspar S, Brault L, Sanders M, Juge S, Morettini S, Tzankov A, Iacovino M, Lau IJ, Milne T, Royo H, Kyba M, Valk PJM, Peters AHFM., Schwaller J (2016) MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing emt-related genes linked to poor outcome. Cancer Cell 30(1):43–58PubMedCrossRef
242.
Zhang X, Ma W, Cui J, Yao H, Zhou H, Ge Y, Xiao L, Hu X, Liu BH, Yang J, Li YY, Chen S, Eaves CJ, Wu D, Zhao Y (2015) Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia. Oncogene 34(23):3000–3010PubMedCrossRef
243.
Thathia S, Ferguson S, Gautrey H, van Otterdijk S, Hili M, Rand V, Moorman A, Meyer S, Brown R, Strathdee G (2012) Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 97(3):371–378PubMedPubMedCentralCrossRef
244.
Nakahata S, Yamazaki S, Nakauchi H, Morishita K (2010) Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene 29(29):4157–4169PubMedCrossRef
245.
Mishra A, La Perle K, Kwiatkowski S, Sullivan L, Sams G, Johns J, Curphey D, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner J, Porcu P, Caligiuri M (2016) Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov 6(9):986–1005PubMedPubMedCentralCrossRef
246.
Cui J, Gong M, He Y, Li Q, He T, Bi Y (2016) All-trans retinoic acid inhibits proliferation, migration, invasion and induces differentiation of hepa1-6 cells through reversing EMT in vitro. Int J Oncol 48(1):349–357PubMedCrossRef
247.
248.
Lan L, Deng W, Chen HL, Huo LL, Deng LL, Zhang GY, Luo Y (2016) All-trans retinoic acid improves iodine uptake of thyroid cancer cells via repressing transcriptional activity of β-catenin. Zhonghua yi Xue za Zhi 96(7):553–558PubMed
249.
Metadaten
Titel
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Publikationsdatum
08.06.2018
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 4/2018
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-018-9906-x

Weitere Artikel der Ausgabe 4/2018

Clinical & Experimental Metastasis 4/2018 Zur Ausgabe

Research Paper

Radiation therapy-induced metastasis: radiobiology and clinical implications

Research Paper

Chemotherapy-induced metastasis: mechanisms and translational opportunities

Research Paper

The challenge of drug resistance in cancer treatment: a current overview

Research paper

Potential impact of invasive surgical procedures on primary tumor growth and metastasis

Research Paper

The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration

Research Paper

The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise